Asian Journal of Andrology

INVITED RESEARCH HIGHLIGHT
Year
: 2015  |  Volume : 17  |  Issue : 3  |  Page : 437--438

Prostate cancer screening: and yet it moves!


Maciej Kwiatkowski1, Marco Randazzo3, Luis Kluth3, Lukas Manka3, Andreas Huber2, Franz Recker4 
1 Department of Urology, Cantonal Hospital Aarau, Switzerland; Department of Urology, Academic Hospital Braunschweig, Germany
2 Department of Laboratory Medicine, Cantonal Hospital Aarau, Switzerland

Correspondence Address:
Maciej Kwiatkowski
Department of Urology, Cantonal Hospital Aarau, Switzerland; Department of Urology, Academic Hospital Braunschweig, Germany

The debate of prostate cancer (PCa) screening has been shaped over decades. There is a plethora of articles in the literature supporting as well as declining prostate-specific antigen (PSA) screening. Does screening decrease PCa mortality? With the long-term results of the European Randomized Study of Screening for Prostate (ERSPC) the answer is clearly YES. It moves! However, in medicine there are no benefits without any harm and thus, screening has to be performed in targeted and smart way-or in other words-in a risk-adapted fashion when compared with the way it was done in the past. Here, we discuss the main findings of the ERSPC trials and provide insights on how the future screening strategies should be implemented.


How to cite this article:
Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F. Prostate cancer screening: and yet it moves!.Asian J Androl 2015;17:437-438


How to cite this URL:
Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F. Prostate cancer screening: and yet it moves!. Asian J Androl [serial online] 2015 [cited 2022 Aug 13 ];17:437-438
Available from: https://www.ajandrology.com/article.asp?issn=1008-682X;year=2015;volume=17;issue=3;spage=437;epage=438;aulast=Kwiatkowski;type=0